Stocktoria
Metagenomi Therapeutics, Inc. MGX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-09
Chart by TradingView
1/9
Piotroski F — financial health
-0.61
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $25.2M | $52.3M | $44.8M |
| Operating income | -$96.0M | -$88.9M | -$78.5M |
| Net income | -$87.9M | -$78.1M | -$68.3M |
| Operating cash flow | -$88.9M | -$109.1M | -$91.4M |
| Free cash flow | -$89.5M | -$112.2M | -$101.2M |
| Total assets | $221.1M | $324.6M | $364.8M |
| Total liabilities | $62.5M | $89.7M | $149.7M |
| Shareholders' equity | $158.6M | $234.9M | -$135.6M |
| Ratios | |||
| Operating margin | -380.9% | -170.0% | -175.4% |
| Net margin | -348.5% | -149.3% | -152.5% |
| FCF margin | -354.9% | -214.5% | -226.2% |
| Return on assets | -39.7% | -24.0% | -18.7% |
| Return on equity | -55.4% | -33.2% | 50.3% |
| Current ratio | 7.22 | 6.91 | 4.04 |
| Revenue growth | -51.8% | 16.8% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 787,900 | $1.1M |
| Point72 Asset Management, L.P. | 11,726 | $15,713 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.61 (distress)
- Working capital / assets 0.645
- Retained earnings / assets -1.406
- EBIT / assets -0.434
- Equity / liabilities 2.537
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001785279 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.